SCHEMBL2383244

SCHEMBL2383244

CC(C)(C)OC(=O)N1CCN(c2nc(Cl)nc(-c3ccsc3)n2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.48
GPR119 Q8TDV5 3/20 0.48
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
GBA1 P04062 2/20 0.44
ACHE P22303 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
PTPN11 Q06124 1/20 0.42
MTOR P42345 2/20 0.41
POLB P06746 1/20 0.40
HPGDS O60760 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384006 0.84 GPR119 (0.48) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL15879042 0.80 MEN1 (0.50) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL14387482 0.80 MEN1 (0.50) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL1409174 0.80 GPR119 (0.49) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL3766128 0.80 NPC1 (0.52) GPR119CKS1BSKP1SKP2GBA1
SCHEMBL12455887 0.76 GPR119 (0.45) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL17672137 0.75 GPR119 (0.63) GPR119MEN1KMT2AHTTSMN1; SMN2
SCHEMBL909718 0.74 USP2 (0.56) PIK3CAMEN1KMT2AADORA2AADORA1
SCHEMBL10297496 0.74 GPR119 (0.55) PIK3CAGPR119CKS1BSKP1SKP2
SCHEMBL23175116 0.73 MEN1 (0.47) PIK3CAGPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor HRH4, HRH3, HRH2 PIK3CA 1620/4885GPR119 300/4885CKS1B 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.